App-Quantinova.ai

Less Favorable Post-Operative Outcomes in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Undergoing Non-Cardiac Surgery: A Matched Controls Analysis

Ashish K. Khanna - American Society of Anesthesiologists (ASA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Heart muscle disease

N/A

Survival Outcomes After In-hospital Cardiac Arrest (IHCA) in Mechanically Ventilated Patients. A Single Center Study

Mehdi Ould Chikh - American Society of Anesthesiologists (ASA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

Epinephrine

Pulmonary Hypertension in Pregnancy: A Retrospective Cohort Study (1997-2013)

Marie-Louise Meng - American Society of Anesthesiologists (ASA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Late Cardiovascular Morbidity Following Pediatric Allogeneic Hematopoietic Cell Transplantation

Christine Duncan - European Group for Blood and Marrow Transplantation (EBMT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

N/A

A POWERFUL DRUG-DELIVERY SYSTEM IN REDUCING CARDIO-TOXICITY OF TRASTUZUMAB: A BIO-DISTRIBUTION STUDY USING 99TC RADIOLABELING TECHNIQUE

A. Khanna - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Trastuzumab

Malignant Pheochromocytoma-Induced Cardiomyopathy in a Young Adult

Kristine Santos de Luna - Endocrine Society (ENDO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Catecholamine

The Role of Liothyronine in Acute Cardiac Setting

Sana Hasan - Endocrine Society (ENDO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

Levothyroxine

Pheochromocytoma: How to Predict the Perioperative Outcome: A Review of Literature

Rupendra T Shrestha - Endocrine Society (ENDO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Isosorbide dinitrate

Intracoronary electrocardiography based strategy for treatment of coronary bifurcation lesions: a method for reduction of periprocedural myonecrosis and major cardiac adverse events at 12-months

Vassilev D - European Association of Percutaneous Cardiovascular Intervention (EuroPCR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

The EVEREST II REALISM continued access study: one year outcomes by mitral regurgitation aetiology in high surgical risk patients

Feldman T - European Association of Percutaneous Cardiovascular Intervention (EuroPCR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

N/A

Extra Corporeal Membrane Oxygenation as Treatment Option for Stress Cardiomyopathy Induced by Suicidal Neck Hanging

Kyutae Park - Angioplasty Summit-TCTAP , 2015

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Heart muscle disease

Epinephrine

One at a Time Strategy for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy

Lin Lin - Angioplasty Summit-TCTAP , 2015

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Heart muscle disease

N/A

FIRST PILOT STUDY OF AN IMPLANTABLE LOOP RECORDER (ILR) IN SYSTEMIC SCLEROSIS DETECTS SIGNIFICANT CARDIAC ARRHYTHMIAS WITH CMR ABNORMALITIES

L.A. Bissell - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

N/A

MICRORNAS AS POTENTIAL REGULATORS OF MONOCYTE DIFFERENTIATION AND FUNCTION IN HEART FIBROSIS IN SYSTEMIC SCLEROSIS

M. Rudnik - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

DE-074

CARDIOVASCULAR MR (CMR) EVIDENCE FOR REDUCED LV MASS IN RHEUMATOID ARTHRITIS (RA), SUGGESTING PATHOLOGY OTHER THAN ATHEROSCLEROSIS FOR HEART FAILURE

L.A. Bissell - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

N/A

EFFECT OF TOCILIZUMAB TREATMENT ON QTC INTERVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS WITHOUT CARDIAC SYMPTOMS

I. Yokoe - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

Methotrexate

MYOCARDIAL FIBROGENESIS IN SYSTEMIC SCLEROSIS: INVOLVEMENT OF A NOVEL STROMAL SUB-POPULATION

M. Stellato - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Heart muscle disease

DE-074

IDENTIFICATION OF AT RISK PATIENTS FOR CARDIAC MRI DETERMINED SUB-CLINICAL SSC-CARDIOMYOPATHY (CM)

L.A. Bissell - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Heart muscle disease

Cyclophosphamide

Effect of Tocilizumab Treatment on QTc Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms

I. Yokoe - European Workshop for Rheumatology Research (EWRR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

Methotrexate

Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Heart muscle disease

Cyclophosphamide

Filters

3340 Abstracts